Analysis
Moonshot AI is advancing its own IPO preparations even as it fends off a public accusation from the White House that it covertly distilled Anthropic's Fable model to build Kimi K3, its viral open-weight release. OSTP Director Michael Kratsios has characterized the alleged conduct as industrial-scale theft; a Moonshot employee has pushed back publicly, noting Kimi K3 shipped just 15 days after Fable's own release and arguing the team built "a brand new frontier model" in that window rather than distilling an existing one. AI researchers cited by TechCrunch and the South China Morning Post say there is no public evidence supporting the distillation claim.
The listing push is notable regardless of how the accusation resolves. Kimi K3 is widely regarded as the most capable open-weight model released to date, matching or beating closed frontier systems from both Anthropic and OpenAI on multiple public benchmarks -- an achievement that would ordinarily be an unambiguous positive heading into a public offering, but is now entangled with an active, unproven US government allegation that could shadow investor sentiment through the entire roadshow process.
“The listing push is notable regardless of how the accusation resolves.”
Fortune has framed the moment as part of a broader "great Chinese AI IPO rush," noting that fellow Chinese lab DeepSeek is separately chasing both a fresh private funding round at a targeted $71 billion valuation and its own mainland China listing in parallel. Having two of China's most prominent AI labs pursuing public markets in the same window as Anthropic, OpenAI and SpaceX would make the next 12-18 months the most concentrated stretch of frontier-AI listings the industry has seen.
The accusation against Moonshot lands the same week 25 US tech giants -- including Nvidia, Microsoft and Meta, but not OpenAI or Anthropic -- publicly urged Washington against new restrictions on open-weight AI models. That policy fight is directly relevant to how a Moonshot listing gets priced: if the distillation accusation escalates into actual export-control action or open-weight restrictions targeting Chinese labs, it could materially impair the addressable market for whatever Moonshot lists.
What to watch: whether the White House produces concrete evidence to support its distillation claim before Moonshot's roadshow begins, whether international investors treat the accusation as a genuine legal risk or as unsubstantiated political noise, and whether DeepSeek's parallel listing effort ends up moving faster or slower than Moonshot's given the accusation Moonshot alone is facing.
